ABT vs JNJ vs DXCM Stock Comparison

Abbott Laboratories, Johnson & Johnson and Dexcom Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$186.63B
P/E
39.7x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
2 wins
JNJ Johnson & Johnson
$286.11 +12.7% 1M +46.5% 1Y
Market cap
$681.31B
P/E
42.3x
Revenue (TTM)
$99.34B
Div. yield
0.02%
Pharmaceuticals Healthcare
4 wins
DXCM Dexcom Inc
$83.33 -0.2% 1M +39.5% 1Y
Market cap
$30.72B
P/E
31.0x
Revenue (TTM)
$5.10B
Div. yield
–
Medical Devices Healthcare
6 wins

Head to Head

12 decided of 12

Dexcom leads on 6 of the 12 questions below (Dexcom 6, Johnson & Johnson 4, Abbott Laboratories 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTJNJDXCMLeader
Larger companyMarket capitalisation $186.63B $681.31B $30.72B JNJ
Cheaper on earningsLower P/E, profitable companies only 39.7x 42.3x 31.0x DXCM
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 26.7x 29.1x ABT
Faster revenue growthRevenue growth, trailing twelve months +10.0% +7.8% +13.0% DXCM
More profitableNet margin, trailing twelve months 9.7% 16.2% 19.4% DXCM
Better return on capitalReturn on invested capital 5.7% 17.6% 32.4% DXCM
Less leveragedLower net debt / EBITDA 2.5x 0.8x -0.9x DXCM
Higher dividend yieldTrailing dividend yield 0.02% 0.02% 0.00% ABT
Better 1-year returnPrice return, last 12 months -16.0% +46.5% +39.5% JNJ
Better 5-year returnAnnualised price return, 5 years -3.3%/yr +11.6%/yr -12.4%/yr JNJ
Less volatileAnnualised volatility, 1 year 28.5% 21.2% 37.9% JNJ
Higher overall scoreMean of the five percentile scores vs peers 56/100 65/100 80/100 DXCM

Percentile Scorecard

ABTJNJDXCM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTJNJDXCM
Valuation 74 #65 of 243 84 #104 of 660 67 #82 of 243
Growth 26 #168 of 228 34 #410 of 619 83 #40 of 228
Profitability 82 #41 of 222 94 #39 of 595 100 #1 of 222
Financial Health 33 #167 of 248 39 #416 of 683 59 #103 of 248
Shareholder Returns 65 #56 of 158 73 #123 of 459 91 #15 of 158
Overall 56 65 80
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • JNJ ranked among 695 companies in Pharmaceuticals and Biotechnology
  • DXCM ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTJNJDXCMSPY
1 month +5.4%+12.7%-0.2% -2.0%
3 months -2.4%+9.9%-7.2% -2.8%
6 months +28.5%+26.2%+35.2% +2.0%
Year to date -13.4%+38.3%+25.6% +10.6%
1 year -16.0%+46.5%+39.5% +12.2%
3 years +11.8%+93.8%-17.8% +68.1%
3 years, per year +3.8%+24.7%-6.3% +18.9%
5 years -15.5%+73.4%-48.4% +61.4%
5 years, per year -3.3%+11.6%-12.4% +10.1%
10 years +170.4%+141.5%+411.2% +248.5%
10 years, per year +10.5%+9.2%+17.7% +13.3%

Risk

MeasureABTJNJDXCMSPY
Volatility, 1Y 28.5%21.2%37.9% 13.6%
Downside volatility, 1Y 27.8%20.1%34.3% 13.9%
Beta vs S&P 500, 1Y 0.07-0.090.72 1.00
Return / volatility, 1Y -0.562.191.04 0.90
Max drawdown, 5Y -41.6%-23.6%-66.3% -25.4%
From 52-week high -16.9%0.0%-9.8% -3.2%
52-week high $130.59$286.11$92.34 $779.14
52-week low $82.56$195.25$57.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTJNJDXCM
P/E now vs peer median 40.0xmedian 26.5x 42.8xmedian 17.0x 31.5xmedian 26.5x
P/S now vs peer median 3.9xmedian 2.7x 6.9xmedian 8.4x 6.1xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 21.5xmedian 14.6x 19.7xmedian 18.4x
P/FCF now vs peer median 27.8xmedian 25.4x 33.5xmedian 19.0x 28.3xmedian 25.4x
P/B now vs peer median 3.6xmedian 2.5x 8.4xmedian 2.0x 12.3xmedian 2.5x
PEG now vs peer median -13.92median 0.98 -1.42median 0.43 0.73median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTJNJDXCM
Revenue $48.23B $99.34B $5.10B
Gross profit $27.46B $67.11B $3.24B
Operating income $6.65B $25.19B $1.22B
Net income $4.70B $16.10B $991.00M
Free cash flow $6.76B $20.59B $1.10B
R&D $3.31B $16.08B $608.10M
EPS (diluted) $2.70 $6.57 $2.58
Cash & equivalents $4.05B $16.91B $961.40M
Total debt $31.16B $44.65B $389.80M
Shares (diluted) 1.74B 2.45B 383.50M
Enterprise value $160.49B $601.18B $22.54B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTJNJDXCM
P/E 40.0x 42.8x 31.5x
P/FCF 27.8x 33.5x 28.3x
P/Operating cash flow 21.2x 26.3x 22.0x
P/S 3.9x 6.9x 6.1x
P/B 3.6x 8.4x 12.3x
P/Tangible book 5.9x 19.7x 12.7x
EV/EBITDA 20.3x 21.5x 19.7x
EV/EBIT 32.3x 28.4x 24.2x
EV/Revenue 4.5x 7.2x 5.8x
EV/FCF 31.8x 34.8x 27.0x
EV/Operating cash flow 24.3x 27.4x 21.0x
PEG (3Y EPS CAGR) -13.92 -1.42 0.73

Growth

14 metrics
MetricABTJNJDXCM
Revenue growth (1Y) 10.0% 7.8% 13.0%
Revenue CAGR (3Y) 6.5% -14.5% 14.5%
Gross profit growth (1Y) 12.1% 7.0% 21.5%
Gross profit CAGR (3Y) 7.8% -12.3% 14.2%
Operating income growth (1Y) -13.8% 7.4% 57.4%
Operating income CAGR (3Y) 3.5% -12.8% 34.2%
Net income growth (1Y) -66.4% -35.9% 37.5%
Net income CAGR (3Y) -3.1% -31.0% 38.0%
EPS growth (1Y) -66.1% -36.4% 46.1%
EPS CAGR (3Y) -2.9% -30.1% 43.0%
Operating cash flow growth (1Y) -2.9% 8.1% -2.3%
Operating cash flow CAGR (3Y) 10.6% 11.4% 23.7%
Free cash flow growth (1Y) -2.3% 5.1% 3.4%
Free cash flow CAGR (3Y) 14.6% 8.8% 30.0%

Profitability

14 metrics
MetricABTJNJDXCM
Gross margin 56.9% 67.6% 63.4%
EBITDA margin 21.9% 33.5% 29.5%
Operating margin 13.8% 25.4% 24.0%
Pretax margin 13.6% 17.9% 24.7%
Net margin 9.7% 16.2% 19.4%
FCF margin 14.0% 20.7% 21.5%
Operating cash flow margin 18.4% 26.3% 27.7%
Return on equity 9.1% 19.3% 38.4%
Return on assets 4.3% 8.1% 15.6%
Return on invested capital 5.7% 17.6% 32.4%
Return on capital employed 7.2% 17.5% 29.9%
Asset turnover 0.4x 0.5x 0.8x
Cash conversion (OCF / net income) 1.9x 1.6x 1.4x
Stock comp / revenue 1.5% 1.4% 3.0%

Financial Health

11 metrics
MetricABTJNJDXCM
Debt / assets 28.8% 22.6% 6.2%
Debt / equity 0.6x 0.5x 0.2x
Net debt / EBITDA 2.5x 0.8x -0.9x
Debt / FCF 4.6x 2.2x 0.4x
Liabilities / assets 52.3% 58.7% 59.4%
Equity / assets 47.7% 41.3% 40.6%
Interest coverage 6.7x 25.6x –
Current ratio 1.5x 1.0x 1.7x
Quick ratio 0.8x 0.7x 1.3x
Cash ratio 0.3x 0.3x 0.8x
Altman Z-score 3.36 5.69 7.53

Shareholder Returns

7 metrics
MetricABTJNJDXCM
Dividend yield 2.3% 1.8% –
Net buyback yield 0.7% 0.6% 2.2%
Shareholder yield 3.0% 2.4% 2.2%
Payout ratio (earnings) 92.0% 79.0% –
Payout ratio (FCF) 64.0% 61.8% –
Dividend growth (1Y) 6.9% 3.9% –
Dividend CAGR (3Y) 7.4% 2.8% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTJNJDXCM
Forward P/E 19.1xFY2026 26.7xFY2026 29.1xFY2026
EPS, next fiscal year $5.69FY2026 $10.72FY2026 $2.86FY2026
EPS growth, next FY +10.5%FY2026 -0.6%FY2026 +36.8%FY2026
EPS growth, the year after +10.2% +5.8% +4.2%
Revenue, next fiscal year $52.99BFY2026 $106.55BFY2026 $5.08BFY2026
Revenue growth, next FY +19.5%FY2026 +13.1%FY2026 +9.0%FY2026
Revenue growth, the year after -2.3% +6.8% +16.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTJNJDXCM
Held by institutions 79.2% 74.7% 100.0%
Institutions holding 2,983 4,699 977
Change in shares held, QoQ +0.3% +1.8% +6.3%
Institutions buying 1,261 2,297 521
Institutions selling 1,379 1,899 345
Buyers to sellers 0.91 1.21 1.51

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTJNJDXCM
ABT 1.00 0.29 0.36
JNJ 0.29 1.00 0.09
DXCM 0.36 0.09 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, JNJ and DXCM?

Johnson & Johnson (JNJ) is the largest by market capitalisation: Abbott Laboratories (ABT) $186.63B, Johnson & Johnson (JNJ) $681.31B, Dexcom (DXCM) $30.72B.

Which stock is cheaper, ABT, JNJ and DXCM?

Dexcom (DXCM) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 39.7x, Johnson & Johnson (JNJ) 42.3x, Dexcom (DXCM) 31.0x). On next year's consensus earnings, Abbott Laboratories (ABT) is cheapest (Abbott Laboratories (ABT) 19.1x, Johnson & Johnson (JNJ) 26.7x, Dexcom (DXCM) 29.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Dexcom (DXCM) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Johnson & Johnson (JNJ) +7.8%, Dexcom (DXCM) +13.0%.

Which company is more profitable?

Dexcom (DXCM) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Johnson & Johnson (JNJ) 16.2%, Dexcom (DXCM) 19.4%). On return on invested capital, Dexcom (DXCM) leads (Abbott Laboratories (ABT) 5.7%, Johnson & Johnson (JNJ) 17.6%, Dexcom (DXCM) 32.4%).

Which stock has performed better?

Over the past year Johnson & Johnson (JNJ) returned the most: Abbott Laboratories (ABT) -16.0%, Johnson & Johnson (JNJ) +46.5%, Dexcom (DXCM) +39.5%. Over five years, Johnson & Johnson (JNJ) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Johnson & Johnson (JNJ) +11.6%/yr, Dexcom (DXCM) -12.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Abbott Laboratories (ABT) has the highest dividend yield: Abbott Laboratories (ABT) 0.02%, Johnson & Johnson (JNJ) 0.02%, Dexcom (DXCM) 0.00%. Dexcom (DXCM) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Johnson & Johnson (JNJ) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Johnson & Johnson (JNJ) 21.2%, Dexcom (DXCM) 37.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, JNJ and DXCM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Dexcom (DXCM) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.